Pfizer Duchenne Program Discontinuation

Pfizer Duchenne Program Discontinuation:

Pfizer has officially decided to discontinue their microdystrophin gene therapy program for Duchenne, after the sad announcement last month that the Phase 3 trial failed to meet its primary endpoint.  While this is not the outcome we had hoped for, we thank Pfizer for its commitment to sharing the data so that the community can continue to learn from their efforts.  We are also grateful to the individuals with Duchenne and their families who have participated in the trials.  CureDuchenne will continue to support you, and continue to work towards more transformative treatments for everyone with Duchenne.

Pfizer Duchenne Program Discontinuation letter to the community below: